Analysts Issue Forecasts for CLDX Q1 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for Celldex Therapeutics in a report released on Friday, February 28th. HC Wainwright analyst J. Pantginis forecasts that the biopharmaceutical company will post earnings per share of ($0.73) for the quarter. HC Wainwright has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share.

Other equities analysts also recently issued research reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. The Goldman Sachs Group lowered their price objective on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a research report on Monday. Finally, UBS Group started coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $44.00 target price for the company. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Celldex Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $55.38.

Celldex Therapeutics Stock Down 5.9 %

NASDAQ CLDX opened at $19.35 on Monday. Celldex Therapeutics has a 52 week low of $19.31 and a 52 week high of $53.18. The firm has a 50 day moving average of $23.75 and a two-hundred day moving average of $28.80. The stock has a market capitalization of $1.28 billion, a PE ratio of -7.53 and a beta of 1.60.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.02. The business had revenue of $1.18 million during the quarter, compared to analysts’ expectations of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%.

Hedge Funds Weigh In On Celldex Therapeutics

A number of institutional investors have recently modified their holdings of CLDX. EverSource Wealth Advisors LLC increased its stake in Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 878 shares during the period. KBC Group NV raised its stake in Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 495 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Celldex Therapeutics during the 4th quarter worth approximately $81,000. AlphaQuest LLC grew its stake in shares of Celldex Therapeutics by 171.0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new position in shares of Celldex Therapeutics in the fourth quarter valued at approximately $121,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.